摘要
大量的证据表明了半胱天冬酶在神经障碍性疾病发展中的作用,包括阿尔茨海默病(AD)。因此,调节半胱天冬酶的活性已经被认为是药物作用靶点 。然而,由于不可控制的副作用,所有关于AD治疗剂pan-caspase抑制剂 的应用都以失败告终。或者,通过敲除caspase-3 基因特定干预RNA (RNAi),可以作为一种极具有潜力的治疗策略。当前研究的目的是,利用慢病毒载体介导的半胱氨酸天冬氨酸蛋白酶短发卡RNA(LV-Caspase-3 shRNA)来下调半胱氨酸天冬氨酸蛋白酶。利用原代大脑皮层神经元和C57BL/6J 小鼠验证,研究了 LV-Caspase-3 shRNA在由铝诱导的凋亡中的作用。这些结果表明凋亡蛋白的增加和半胱氨酸天冬氨酸蛋白酶在原代大脑皮层神经元中的表达和暴露在Al中的小鼠皮质,都可以通过LV-Caspase-3 shRNA来下调。此外,LV-Caspase-3 shRNA降低了神经元细胞的死亡和增强Al处理的C57BL/6J 小鼠的学习和记忆能力。我们的结果表明LV-Caspase-3 shRNA是一个潜在的治疗药物用于防止在铝暴露的动物模型中的神经退行性病变和认知障碍。这些发现提供了一个合理的AD基因治疗策略。
关键词: 细胞凋亡,阿尔茨海默病,半胱天冬酶3,调节caspase-3 shRNA的慢病毒载体,RNA干扰
Current Alzheimer Research
Title:Caspase-3 Short Hairpin RNAs: A Potential Therapeutic Agent in Neurodegeneration of Aluminum-Exposed Animal Model
Volume: 11 Issue: 10
Author(s): Qinli Zhang, Na Li, Xia Jiao, Xiujun Qin, Ramanjit Kaur, Xiaoting Lu, Jing Song, Linping Wang, Junming Wang and Qiao Niu
Affiliation:
关键词: 细胞凋亡,阿尔茨海默病,半胱天冬酶3,调节caspase-3 shRNA的慢病毒载体,RNA干扰
摘要: There is abundant evidence supporting the role of caspases in the development of neurodegenerative disease, including Alzheimer’s disease (AD). Therefore, regulating the activity of caspases has been considered as a therapeutic target. However, all the efforts on AD therapy using pan-caspase inhibitors have failed because of uncontrolled adverse effects. Alternatively, the specific knockdown of caspase-3 gene through RNA interference (RNAi) could serve as a future potential therapeutic strategy. The aim of the present study is to down-regulate the expression of caspase-3 gene using lentiviral vector-mediated caspase-3 short hairpin RNA (LV-Caspase-3 shRNA). The effect of LV-Caspase-3 shRNA on apoptosis induced by aluminum (Al) was investigated in primary cultured cortical neurons and validated in C57BL/6J mice. The results indicated an increase in apoptosis and caspase-3 expression in primary cultured neurons and the cortex ofmice exposed to Al, which could be down-regulated by LV-Caspase-3 shRNA. Furthermore, LV-Caspase-3 shRNA reduced neural cell death and improved learning and memory in C57BL/6J mice treated with Al. Our results suggest that LV-caspase-3 shRNA is a potential therapeutic agent to prevent neurodegeneration and cognitive dysfunction in aluminum- exposed animal models. The findings provide a rational gene therapy strategy for AD.
Export Options
About this article
Cite this article as:
Qinli Zhang, Na Li, Xia Jiao, Xiujun Qin, Ramanjit Kaur, Xiaoting Lu , Jing Song, Linping Wang, Junming Wang and Niu Qiao, Caspase-3 Short Hairpin RNAs: A Potential Therapeutic Agent in Neurodegeneration of Aluminum-Exposed Animal Model, Current Alzheimer Research 2014; 11 (10) . https://dx.doi.org/10.2174/1567205011666141107150938
DOI https://dx.doi.org/10.2174/1567205011666141107150938 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antibacterial Combination of Oleoresin from Copaifera multijuga Hayne and Biogenic Silver Nanoparticles Towards Streptococcus agalactiae
Current Pharmaceutical Biotechnology Desferrioxamine as Immunomodulatory Agent During Microorganism Infection
Current Pharmaceutical Design Colloidal Supramolecular Aggregates for Therapeutic Application in Neuromedicine
Current Medicinal Chemistry Antisense Oligonucleotides as an Innovative Therapeutic Strategy in the Treatment of High-Grade Gliomas
Recent Patents on CNS Drug Discovery (Discontinued) Mucopolysaccharidosis Type III (Sanfilippo Syndrome): Emerging Treatment Strategies
Current Pharmaceutical Biotechnology Phytochemicals to Prevent Inflammation and Allergy
Recent Patents on Inflammation & Allergy Drug Discovery Potential Drugs Targeting Microglia: Current Knowledge and Future Prospects
CNS & Neurological Disorders - Drug Targets Neuroprotection and Hypothermia in Infants and Children
Current Drug Targets The Correspondence Between Magnetic Resonance Images and the Clinical and Intraoperative Status of Patients with Spinal Tumors
Current Medical Imaging Antimicrobial Stewardship in the Neonatal Intensive Care Unit: An Update
Current Pediatric Reviews Drugs, Trials and Pathogenesis: Will Connecting these Help us Understand SLE?
Current Rheumatology Reviews Recent Patents on Proteases and Kinases as Anti-Infective Agents: A Review
Recent Patents on Anti-Infective Drug Discovery Modulation of the Human Gut Microflora Towards Improved Health Using Prebiotics - Assessment of Efficacy
Current Pharmaceutical Design Neuroinflammation in Sepsis: Sepsis Associated Delirium
Cardiovascular & Hematological Disorders-Drug Targets Potential Antibacterial Activity of Yemeni Sidr Honey Against <i>Pseudomonas aeruginosa</i> and <i>Streptococcus pyogenes</i>
Anti-Infective Agents QSAR Studies on HSV-1 Inhibitors by CoMFA, CoMSIA and HQSAR Approaches
Letters in Drug Design & Discovery Conference Report: (Annual Advances in Neurorestoratology: A Summary of IANR VI and 10th GCNN Conference, Bucharest, Romania, April 4-7, 2013)
CNS & Neurological Disorders - Drug Targets Synthesis of Imidazo[1,2-b]pyridazine Comprised Piperazine, Morpholine Derivatives as Potent Antimycobacterial Agents with In Vivo Locomotor Activity
Anti-Infective Agents Central Nervous System Disorders Associated to Immune Checkpoint Inhibitors
Current Cancer Therapy Reviews Current Understanding on Biosynthesis of Microbial Polysaccharides
Current Topics in Medicinal Chemistry